MetLife Investment Management LLC Sells 375 Shares of United Therapeutics Corporation $UTHR

MetLife Investment Management LLC lessened its holdings in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 1.5% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 24,775 shares of the biotechnology company’s stock after selling 375 shares during the period. MetLife Investment Management LLC’s holdings in United Therapeutics were worth $7,637,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of the stock. Hohimer Wealth Management LLC lifted its stake in United Therapeutics by 0.3% during the 1st quarter. Hohimer Wealth Management LLC now owns 12,651 shares of the biotechnology company’s stock valued at $3,900,000 after acquiring an additional 37 shares during the period. Applied Finance Capital Management LLC lifted its stake in United Therapeutics by 3.7% during the 1st quarter. Applied Finance Capital Management LLC now owns 1,132 shares of the biotechnology company’s stock valued at $349,000 after acquiring an additional 40 shares during the period. Headlands Technologies LLC lifted its stake in United Therapeutics by 1.5% during the 1st quarter. Headlands Technologies LLC now owns 2,687 shares of the biotechnology company’s stock valued at $828,000 after acquiring an additional 40 shares during the period. Cadence Bank lifted its stake in United Therapeutics by 1.2% during the 1st quarter. Cadence Bank now owns 3,963 shares of the biotechnology company’s stock valued at $1,222,000 after acquiring an additional 47 shares during the period. Finally, Dunhill Financial LLC lifted its stake in United Therapeutics by 100.0% during the 4th quarter. Dunhill Financial LLC now owns 100 shares of the biotechnology company’s stock valued at $35,000 after acquiring an additional 50 shares during the period. Institutional investors own 94.08% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have issued reports on UTHR. Cantor Fitzgerald restated an “overweight” rating on shares of United Therapeutics in a research note on Thursday, August 14th. JPMorgan Chase & Co. lowered their target price on shares of United Therapeutics from $350.00 to $330.00 and set an “overweight” rating on the stock in a research note on Tuesday, July 8th. UBS Group upped their price target on shares of United Therapeutics from $385.00 to $415.00 and gave the company a “buy” rating in a research report on Wednesday, August 13th. Wall Street Zen lowered shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Friday, May 2nd. Finally, Wells Fargo & Company reduced their price target on shares of United Therapeutics from $314.00 to $295.00 and set an “equal weight” rating for the company in a research report on Thursday, July 31st. Nine analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat, United Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $382.00.

Insider Activity

In related news, CFO James Edgemond sold 12,000 shares of the stock in a transaction that occurred on Monday, June 9th. The shares were sold at an average price of $325.37, for a total value of $3,904,440.00. Following the completion of the sale, the chief financial officer directly owned 8,118 shares of the company’s stock, valued at approximately $2,641,353.66. This represents a 59.65% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Nilda Mesa sold 645 shares of the stock in a transaction that occurred on Tuesday, June 24th. The stock was sold at an average price of $289.99, for a total transaction of $187,043.55. Following the completion of the sale, the director directly owned 4,883 shares of the company’s stock, valued at $1,416,021.17. This represents a 11.67% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 81,681 shares of company stock valued at $24,537,839. 10.30% of the stock is owned by insiders.

United Therapeutics Stock Down 1.3%

NASDAQ UTHR opened at $305.35 on Thursday. United Therapeutics Corporation has a 52 week low of $266.98 and a 52 week high of $417.82. The firm has a market capitalization of $13.77 billion, a P/E ratio of 11.92, a PEG ratio of 4.69 and a beta of 0.57. The company has a 50-day moving average price of $298.07 and a 200-day moving average price of $306.73.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share (EPS) for the quarter, missing the consensus estimate of $6.80 by ($0.39). The firm had revenue of $798.60 million during the quarter, compared to analysts’ expectations of $802.13 million. United Therapeutics had a return on equity of 18.73% and a net margin of 40.36%.The company’s revenue was up 11.7% compared to the same quarter last year. During the same period in the prior year, the company posted $5.85 earnings per share. As a group, equities research analysts anticipate that United Therapeutics Corporation will post 24.48 EPS for the current year.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.